Can adding a targeted pill to chemo beat resistant lung cancer?

NCT ID NCT04765059

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 40 times

Summary

This Phase 3 trial tests whether adding the targeted drug osimertinib to standard chemotherapy can help people with advanced EGFR-mutant non-small cell lung cancer whose disease has progressed after initial osimertinib treatment. About 98 participants will receive either osimertinib plus chemo or a placebo plus chemo. The main goal is to see if the combination delays cancer growth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Research Site

Silver Spring, Maryland, 20910, United States
Research Site

Boston, Massachusetts, 02114, United States
Research Site

Beijing, 100005, China
Research Site

Beijing, 100142, China
Research Site

Ganzhou, 341099, China
Research Site

Guangzhou, 510080, China
Research Site

Jinan, 250013, China
Research Site

Shenyang, 110001, China
Research Site

Tianjin, 300060, China
Research Site

Zhengzhou, 450008, China
Research Site

Berlin, 12351, Germany
Research Site

Cologne, 50937, Germany
Research Site

Cologne, 51109, Germany
Research Site

Hanover, 30625, Germany
Research Site

München, D-80336, Germany
Research Site

Beersheba, 84101, Israel
Research Site

Jerusalem, 9103102, Israel
Research Site

Jerusalem, 9112001, Israel
Research Site

Kfar Saba, 4428164, Israel
Research Site

Tel Aviv, 6423906, Israel
Research Site

Tel Litwinsky, 52621, Israel
Research Site

Florence, 50134, Italy
Research Site

Meldola, 47014, Italy
Research Site

Messina, 98158, Italy
Research Site

Naples, 80131, Italy
Research Site

Padova, 35128, Italy
Research Site

Roma, 00168, Italy
Research Site

Terni, 05100, Italy
Research Site

Verona, 37124, Italy
Research Site

Alicante, 03010, Spain
Research Site

Barcelona, 08907, Spain
Research Site

Córdoba, 14004, Spain
Research Site

León, 24071, Spain
Research Site

Madrid, 28040, Spain
Research Site

Málaga, 29010, Spain
Research Site

Murcia, 30008, Spain
Research Site

Oviedo, 33011, Spain
Research Site

Palma de Mallorca, 07010, Spain
Research Site

Seville, 41013, Spain
Research Site

Valencia, 46010, Spain

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Osimertinib (a targeted cancer pill) combined with chemotherapy (pemetrexed plus cisplatin or carboplatin)

What this could lead to

If successful, this could offer a new treatment option for people with EGFR-mutant lung cancer whose disease has worsened after initial osimertinib therapy.

What could go wrong

This is a relatively small Phase 3 trial (98 participants) and results may not apply to all patients. Adding osimertinib to chemo may increase side effects without improving outcomes.

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER